Soriot declines to quantify a post-2030 target for now, but says pipeline strength underpins confidence in growth beyond 2030.
I think it's a little bit too early, to be honest. The -- and I'll explain why in a second, the reason why we are confident of growing post 2030 is the strength of the pipeline we have in our hands.
All statements by Pascal Soriot ›
Soriot cautions that biology and disease are too complex, so claims that AI will cure cancer are overstated.
If we remain active in the industry long enough, we quickly learn to be humble. Diseases are complicated, biology is complicated. Claiming that AI will cure cancer may be going a little too far,
Soriot said 20 upcoming high-value trial readouts could create over $20 billion in peak annual revenue, with a significant part materializing in coming years.
Over the next year, 20 “high-value trial readouts” could, if positive, yield peak annual revenue opportunities surpassing $20 billion. “A significant part” of that total should “become reality over the next few years,” Soriot proclaimed.
Soriot said embedding AI more deeply lets AstraZeneca grow without adding as much headcount, making the company faster and smarter.
AI is helping "make us faster, smarter," Soriot said. AstraZeneca can "grow without growing," meaning it can "grow without adding as many people as you would have if you didn't have the use of AI."
Soriot said AstraZeneca's pipeline momentum and 20 upcoming high-value readouts could deliver over $20 billion in peak revenue, with a significant part materializing in coming years.
Since February, the company has reported positive results from 12 late-stage programs and brought four new drugs to market, CEO Pascal Soriot told analysts. Over the next year, 20 "high-value trial readouts" could, if positive, yield peak annual revenue opportunities surpassing $20 billion. "A significant part" of that total should "become reality over the next few years," Soriot proclaimed.
Soriot says combining Tagrisso with Orpathys can broaden first-line use and extend treatment duration, shielding the franchise from new competitors.
The combination with Orpathys has the potential to drive both broader first-line use as well as longer Tagrisso-based treatment duration, keeping patients on Tagrisso rather than switching them off and therefore, protecting the franchise from newcomers.